E2F1 and neoplasm: We observed a stepwise increase in both E2F1 expression and proportion of E2F1+ cells from P0 to P3 cells (Supplementary Fig. 14), suggesting that E2F1 upregulation in P3 tumor cells results from the immune pressure–driven enrichment of pre-existing E2F1+ tumor cells during immunotherapy.